United States - English - NLM (National Library of Medicine)

mylan institutional llc - dexrazoxane hydrochloride (unii: 5346058q7s) (dexrazoxane - unii:048l81261f) - dexrazoxane 250 mg in 25 ml - dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. do not use with the initiation of doxorubicin therapy [see warnings and precautions (5.2)] . do not use dexrazoxane for injection with non-anthracycline chemotherapy regimens. dexrazoxane for injection can cause fetal harm when administered to pregnant women. dexrazoxane administration resulted in maternal toxicity, embryotoxicity and teratogenicity in rats and rabbits at doses significantly lower than the clinically recommended dose. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see warnings and precautions (5.5)] . dexrazoxane resulted in maternal toxicity in rats at doses of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - sumatriptan succinate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ciprofibrate - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - terbinafine hydrochloride - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - celecoxib - oral capsule - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - sumatriptan succinate - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

nova-tech, inc. - dextrose h2 o...........................50% w/v, water for injection...................q.s. - dextrose 50% solution is indicated for use as an aid in the treatment of uncomplicated primary ketosis in cattle.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - nadolol 40mg;  ;   - tablet - 40 mg - active: nadolol 40mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prophylaxis of angina pectoris

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - nadolol 80mg;  ;   - tablet - 80 mg - active: nadolol 80mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prophylaxis of angina pectoris

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate dimeticone mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.